Related Experiment Video
Updated: Jul 18, 2026
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists
R R Hantgan1, M C Stahle, J H Connor
1Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1019, USA. hantgan@wfubmc.edu
Insights
Glycoprotein IIb/IIIa inhibitors, while blocking platelet interactions, can paradoxically increase thrombosis risk by leaving the alpha(IIb)beta(3) receptor in an activated state. Understanding these mechanisms is key to improving safety and efficacy.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biochemistry
Background:
- Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonists are crucial in percutaneous coronary interventions.
- These drugs block platelet aggregation but can paradoxically increase thrombosis risk.
- Understanding GP IIb/IIIa inhibitor mechanisms is vital for patient safety.
Purpose of the Study:
- To test if blocking fibrinogen binding activates the alpha(IIb)beta(3) receptor.
- To compare the effects of oral (orbofiban, roxifiban) and IV (eptifibatide, tirofiban) agents, plus echistatin, on platelet function and receptor conformation.
Main Methods:
- Flow cytometry, aggregometry, and adhesion assays determined antagonist concentrations for platelet saturation and interaction blocking.
- Analytical ultracentrifugation assessed effects on alpha(IIb)beta(3) solution structure.
- Fluorescence anisotropy provided equilibrium and kinetic data for integrin:antagonist interactions.
Main Results:
- Oral drugs (orbofiban, roxifiban) bound tighter and inhibited aggregation/adhesion more than echistatin.
- The order of perturbing alpha(IIb)beta(3) conformation and promoting clustering was: echistatin > eptifibatide > orbofiban > tirofiban > roxifiban.
- Roxifiban most effectively disrupted the alpha(IIb)beta(3):echistatin complex.
Conclusions:
- GP IIb/IIIa inhibitors' tight binding and fibrinogen blocking ability also perturb resting integrin conformation.
- This conformational change limits the safety and efficacy of both oral and IV integrin antagonists.
- Further research into these mechanisms can optimize antiplatelet therapies.
Background:
Drugs that block platelet-platelet and platelet-fibrin interactions via the alpha(IIb)beta(3) (glycoprotein IIb/IIIa) receptor are used daily in patients undergoing percutaneous coronary interventions. Along with expected increases in spontaneous bleeding, clinical trials have revealed a surprising increase in thrombosis when these drugs are used without other anticoagulants. A better understanding of their mechanisms can minimize these risks.
Objectives:
This study tested the hypothesis that interventions designed to block fibrinogen binding inevitably leave the alpha(IIb)beta(3) receptor in an activated state. It compared the effects on platelet function and alpha(IIb)beta(3) conformation of the orally active compounds orbofiban and roxifiban, the i.v. agents eptifibatide and tirofiban, and echistatin, an arginine-glycine-aspartate (RGD) disintegrin.
Methods:
The integrin antagonist concentrations required to saturate platelets and to block platelet-platelet and platelet-fibrin interactions were determined by flow cytometry, aggregometry, and clot-based adhesion assays, respectively. Analytical ultracentrifugation measured each antagonist's effects on the solution structure of alpha(IIb)beta(3). Fluorescence anisotropy provided equilibrium and kinetic data for integrin:antagonist interactions.
Results:
Both orally active drugs bound more tightly and inhibited platelet aggregation and adhesion to fibrin more effectively than echistatin. Analytical ultracentrifugation yielded this order for perturbing alpha(IIb)beta(3) conformation (priming) and promoting oligomerization (clustering): echistatin > eptifibatide > orbofiban > tirofiban > roxifiban. Roxifiban was also most effective at disrupting the rapidly forming/slowly dissociating alpha(IIb)beta(3):echistatin complex.
Conclusions:
Our results suggest that the same molecular mechanisms that enable glycoprotein IIb/IIIa inhibitors to bind tightly to the alpha(IIb)beta(3) receptor and block fibrinogen binding contribute to their ability to perturb the resting integrin's conformation, thus limiting the safety and efficacy of both oral and i.v. integrin antagonists.
More Related Videos
10:50Isolation of Labile Multi-protein Complexes by in vivo Controlled Cellular Cross-Linking and Immuno-magnetic Affinity Chromatography
Published on: March 9, 2010
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.